# Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

> **NCT00486408** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 35 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** MRKAd5 HIV-1 gag/pol/nef

## Key facts

- **NCT ID:** NCT00486408
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-09
- **Final completion:** 2012-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486408, "Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00486408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*